Angiotech Pharmaceuticals Inc

Angiotech Pharmaceuticals — Q3 2010 Earnings Presentation

19 slides from Angiotech Pharmaceuticals's earnings presentation, Nov 9, 2010

  1. Slide 1: Third Quarter 2010

    Exhibit 99.1 Third Quarter 2010 November 9, 2010

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements Statements contained in this presentation that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimates,” “continues,” “anticipates,” “intends,” “expects” and similar expressions, consti

  3. Slide 3: Financial Information

    3 Financial Information This presentation contains unaudited financial data derived from the unaudited consolidatedfinancial statements for the three and nine months ended September 30, 2010 and certain prior financial periods. Full audited consolidated financial statements and Management’s Discussi

  4. Slide 4: Proxy Statement Legend Language

    4 Proxy Statement Legend Language Additional Information and Where to Find It – This communication may be deemed to be solicitation material in respect of the proposed recapitalization transaction with holders of its Senior Subordinated Notes and Senior Floating Rate Notes, as announced on October 2

  5. Slide 5: Financial Review

    = x Angiotech Redefining Success~ 1 2 BeemeARMACEUTICALS inc =n aE

  6. Slide 6: Three Business Units

    6 Three Business Units Different Growth and Financial Characteristics Proprietary Base Royalty Ophthalmic Biopsy General sutures OEM Surgical: 50 direct sales reps Interventional: 50 direct sales reps $17.3M $34.5M $7.1M +18% vs. Q3:09 +1% vs Q3:09 (51%) vs Q3:09 +18% constant currency +3% constant

  7. Slide 7: Q3:10 Financial Results

    7 Q3:10 Financial Results Quarter Comparisons ($M ex per share items) Q3:09 Q2:10 Q3:10 Revenue Proprietary $14.7 $16.4 $17.3 18% Base $33.8 $36.7 $34.5 2% Royalty $14.5 $8.9 $7.1 (51%) Gross Margin % (Product) 48.2% 49.1% 50.5% Op Expenses R&D $4.1 $6.7 $6.1 SG&A $17.1 $21.1 $21.9 Results Adjusted

  8. Slide 8: Q3:10 Financial Results: Trends from Q1:08

    8 Q3:10 Financial Results Trends from Q1:08 ($M) Proprietary Revenue Base Revenue $25 $30 $20 $25 $24 $23 $24 $18 $22 $23 $22 $22 $22 $17 $21 $21 $21 $16 $16 $15 $20 $15 $13 $13 $15 $15 $15 $12 $11 $12 $15 $10 $12 $13 $12 $13 $13 $12 $11 $11 $10 $10 $5 $5 $0 $0 Q1:08 Q2:08 Q3:08 Q4:08 Q1:09 Q2:09 Q3

  9. Slide 9: Selected Balance Sheet, Cash Flow Items and Credit Statistics

    9 Q3:10 Financial Results Selected Balance Sheet, Cash Flow Items and Credit Statistics $US in millions Sept 30, 2009 June 30, 2010 Sept 30, 2010 Assets Cash and cash equivalents $51.5 $29.7 $25.6 Short-term investments $2.3 $5.5 $5.7 Accounts receivable $28.9 $30.5 $31.0 Inventories $38.0 $37.9 $38

  10. Slide 10: Selected Highlights and Challenges

    10 Q3:10 Financial Results Selected Highlights and Challenges Highlights Continued proprietary revenue growth Continued base stability / growth Continued focus on expense management Continued focus on cash conservation / management Professional / advisory fees related to proposed transaction Challen

  11. Slide 11: Proposed Recapitalization: Key Facts, Figures, Considerations

    11 Proposed Recapitalization Key Facts, Figures, Considerations Key Facts and Figures Debt for equity exchange (Subordinated Notes) – Coupled with proposed transaction with Senior Floating Rate Notes Interim liquidity facility with Wells Fargo Capital Finance ($25M) Eliminate $250M of Subordinated N

  12. Slide 12: Selected Pro Forma Balance Sheet, Cash Flow Items and Credit Statistics

    12 Q3:10 Financial Results Selected PRO FORMA Balance Sheet, Cash Flow Items and Credit Statistics $US in millions Sept 30, 2009 June 30, 2010 Sept 30, 2010 Cash and cash equivalents $51.5 $29.7 $25.6 PRO FORMA $71.5 $49.6 $45.5 Long-term debt $575.0 $575.0 $575.0 PRO FORMA $325.0 $325.0 $325.0 Net

  13. Slide 13: Proposed Recapitalization: Key Considerations

    13 Proposed Recapitalization Key Considerations Key Considerations Multiple alternatives assessed, solicited, reviewed and considered – Since mid to late 2006 – Post-October 2008 (Blackstone hired) Debt exchange offer – Significant majority of holders have agreed to terms (Subordinated Notes and FRN

  14. Slide 14: Business Review

    Business Review

  15. Slide 15: Business Review: Quill SRS

    15 Business Review TM Quill SRS 1,389 hospital accounts as of Dragon Pattern September 30, 2010 New specialty codes, designs in 6-0 Polypropylene development (urology, specialty orthopedic, others) Suture Diameter: 40 µm 2010 sales force and marketing Barb Depth: 7 µm expansion complete, 2011 planni

  16. Slide 16: Business Review: Zilver PTX

    16 Business Review Zilver® PTX™ Zilver® PTX™(Cook Medical) – potentially groundbreaking technology for peripheral vascular disease (PVD) treatment Zilver platform: – Self expanding nitinol (shape memory metal alloy) – Thin layer of drug (<5 micron) – 3 microgram / mm² dose density / max 880 microgra

  17. Slide 17: Business Review: Base Medical Products

    17 Business Review Base Medical Products Ophthalmic Surgical Biopsy OEM Sharpoint ™ Sharpoint ™ BioPince™ Suture materials Surgical and SharpGuard ™ LOOK™ Hawkins™ microsurgical UltraFit ™ MonoDerm ™ T-Lok™ needles & blades IQ Geometry ™ DermaGlide ™ V-Mark™ Surface M.E.T. ™Needle Tru-Core II™ enhan

  18. Slide 18: Q3:10 Conclusions

    18 Q3:10 Conclusions Continued product sales momentum – Record Q3 results – Strong showing and effort by our team – Proprietary growth (Quill), Base stability Zilver PTX – Excellent data package presented at TCT – Potential approval could mean U.S. sales in H2:11 Recapitalization transaction positio

  19. Slide 19: Angiotech

    = x Angiotech Redefining Success~ 1 2 BeemeARMACEUTICALS inc =n aE

Angiotech Pharmaceuticals — Q3 2010 Earnings Presentation on 6ix